About Us

Dr Lim Kah Meng has dedicated a large part of his research focus on molecular biomedicine. For more than 20 years, he fervently pursued his scientific interests on bioactive molecules that govern and regulate cellular pathways leading to cellular homeostasis and wellbeing. Being credited as the “Father of Molecular Edible Birds Nests”, Dr Lim has filed multiple patents on the extraction processes for the bioactive molecules including immunological active bio-molecules from edible bird nests.

Dr. Lim is also known in this region to be the “Father of Molecular Placenta” where he has successfully developed highly popular products for the commercial world based on placental stem cell extracts.

He has since diversified into stem cell research including products or platforms based on induced pluripotent stem cells for personalized aesthetic and therapeutic for acute illnesses such as diabetes, psoriasis and dementia. Dr. Lim has also published a paper documenting successful clinical cases for 9 cancer patients in Singapore using high done intravenous vitamin C.

On biologics research, Dr Lim has at least a few years of precious experience; working with leading global biologics experts both at Agency for Science, Technology and Research (A*STAR) [Singapore] as well as at University of Minnesota [USA].

Dr Lim is also deep into biomedical research for neuroscience. He has filed for at least 5 patents related to cannabinoids, specifically on medical cannabis but not exclusive to just neurological functions, optimizing bioactive compounds, Dr. Lim’s most recent research is in successfully using micro RNAs as the next generation diagnostic markers for most cancer and chronic diseases detection. Dr Lim was also the recipient for the Singapore award of the 10 outstanding young persons of the world in 2012.

Dr. Lim joined the Singapore PainCare Holdings Ltd as an independent Non-Executive Director in March 2021 and at the same time, serves as an Honorary Advisor of the World LIN Chamber of Commerce, Singapore.

Vic Tham has over three decades of experience in the financial industry, ranging from various roles in the securities and capital markets, banking and fintech industries. Vic’s career included previous appointments as Group Chief Risk Officer for Hong Kong Exchanges and Clearing Limited (HKEX); Chief Operating Officer for Bank of America Merrill Lynch, Asia Global Transaction Services; and as the Managing Director of Standard Chartered Bank WB Operational Risk, North Asia. He also held senior roles at Morgan Stanley, DBS Bank, Jardine Fleming Securities and ABN AMRO Securities in Singapore, Hong Kong and New York.

Vic has extensive experience in risk management, strategic planning and project execution. Throughout his career, he has built, lead and participated in several large Merger & Acquisition (M&A) deals and programmes. Some of his key accomplishments include being part of the Morgan Stanley syndications team representing HK Futures Exchange for a billion-dollar merger to form HKEX.

Recognized for his vast expertise, Vic is a highly regarded keynote speaker and had spoken at over 250+ conferences and events across Asia & China on topics ranging from Risk & Compliance to Fintech relating to Artificial Intelligence, blockchain and digital tokens.

Vic holds the Master of Business Administration (Finance and Accounting) and the Bachelor of Science (Finance & MIS) degrees from the State University of New York at Buffalo, New York, USA. Vic is also Six Sigma trained and certified. He also previously held securities and fund management licenses and registrations with regulators in Singapore, Hong Kong and New York.

Sethu has more than 28 years of pharmaceutical experience comprising of research, quality assurance, and technological commercialization. He was formerly Head of Business for SGS Life Science in Singapore and covered its regional development and Head of Asia Biopharmaspec UK.

He has worked closely with Biosimilar research companies and Biopharma companies to support their technical challenges, having held positions such as Quality Management System Manager in Pfizer Research and Head of Quality for New Drugs in Cipla. He has also worked in Formulation Development of drug products

Sethu is also involved in developing Biomedical Standards in Singapore through SMF. He has also been honored with a prestigious commendation award for his contribution in 2021 by the Enterprise Singapore for his contributions.

Sethu holds Graduate in Chemistry, with certificates in Pharmaceutical Regulatory Affairs and Pharmaceutical GMP (NUS).